View Older Stories View More Recent Stories

May 12, 2020 04:08PM Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131
May 4, 2020 08:13AM Isoray To Announce Third Quarter Fiscal 2020 Financial Results on May 12, 2020
Feb 11, 2020 04:05PM Isoray Announces Second Quarter Fiscal 2020 Financial Results
Feb 5, 2020 08:13AM Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers
Feb 5, 2020 08:13AM Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers
Jan 31, 2020 08:13AM Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020
Jan 31, 2020 08:13AM Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020
Jan 27, 2020 08:00AM GT Medical Technologies Announces FDA Clearance of Expanded Indication for GammaTile Therapy
Nov 12, 2019 04:05PM Isoray Announces Record First Quarter Fiscal 2020 Financial Results
Oct 31, 2019 08:13AM Isoray To Announce First Quarter Fiscal 2020 Financial Results on November 12, 2019
Oct 29, 2019 08:13AM Isoray Will Have Prominent Role at American Brachytherapy Society’s Annual Prostate Brachytherapy Workshop
Sep 24, 2019 04:05PM Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results
Sep 18, 2019 08:13AM A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment
Sep 12, 2019 08:13AM Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019
Sep 10, 2019 08:13AM Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting 
Aug 13, 2019 08:05AM Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies
Jun 12, 2019 08:13AM Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting
May 9, 2019 04:05PM Isoray Announces Record Third Quarter Fiscal 2019 Financial Results
May 1, 2019 08:13AM Isoray To Announce Third Quarter Fiscal 2019 Financial Results on May 9, 2019
Apr 16, 2019 08:11AM Isoray Collaborates With Texas Oncology to Fill Void in Training Programs For Next Generation of Brachytherapists
Feb 12, 2019 04:05PM Isoray Announces Second Quarter Fiscal 2019 Financial Results
Jan 30, 2019 08:13AM Isoray To Announce Second Quarter Fiscal 2019 Financial Results on February 12, 2019
Jan 29, 2019 08:13AM Medical University of South Carolina Performs World’s First Prostate Cancer Surgery Using Blu Build Brachytherapy System
Dec 17, 2018 08:16AM IsoRay (ISR) Announces Appointment of Lori Woods as CEO
Dec 17, 2018 08:13AM IsoRay Announces the Appointment of Lori Woods As Chief Executive Officer
Dec 3, 2018 08:14AM IsoRay (ISR) Names Jonathan Hunt as CFO
Dec 3, 2018 08:13AM IsoRay Names Jonathan Hunt New Chief Financial Officer
Nov 8, 2018 04:05PM IsoRay Announces First Quarter Fiscal 2019 Financial Results
Oct 24, 2018 08:13AM IsoRay To Announce First Quarter Fiscal 2019 Financial Results on November 8, 2018
Sep 25, 2018 04:05PM IsoRay Announces Fourth Quarter and Full-Year 2018 Financial Results
Sep 10, 2018 08:15AM IsoRay To Announce Fourth Quarter and Year End 2018 Financial Results on September 25, 2018
Jul 12, 2018 08:30AM IsoRay, Inc. Closes $8,250,000 Registered Direct Offering
Jul 9, 2018 01:53PM IsoRay (ISR) Confirms FDA Clearance of GammaTile Therapy for Treatment of Recurrent Brain Neoplasms
Jul 9, 2018 01:52PM IsoRay Announces FDA Clearance of GammaTile™ Therapy for the Treatment of Recurrent Brain Neoplasms
Jun 19, 2018 08:05AM IsoRay (ISR) Reports Employment Agreement with Lori A. Woods as Interim CEO
Jun 19, 2018 08:00AM IsoRay Announces Entry into Employment Agreement with Lori A. Woods as Interim CEO
Jun 5, 2018 08:11AM IsoRay (ISR) Announces Resignation of Chairman and CEO Thomas LaVoy; Lori Woods Appointed Interim CEO; Mick McCormick Appointed Chairman
Jun 5, 2018 08:00AM IsoRay Announces the Resignation of Chairman and CEO Thomas LaVoy; Industry Veteran Lori Woods Appointed Interim CEO; Mick McCormick Appointed Chairman of the Board
May 30, 2018 08:00AM IsoRay Announces Signing of Research Funding with Ochsner Clinic Foundation to Support Brain Cancer Treatment Research
May 16, 2018 08:30AM IsoRay Announces Participation at the American Urological Association’s 2018 Annual Meeting, May 18-21, 2018
May 11, 2018 08:30AM IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment
May 3, 2018 04:05PM IsoRay Announces Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Third Quarter-Over-Third Quarter Increase
May 2, 2018 08:30AM IsoRay to Present at the 3rd Annual Disruptive Growth & Healthcare Conference hosted by RHK Capital
Apr 26, 2018 08:00AM IsoRay Announces Third Quarter Fiscal 2018 Earnings Conference Call
Apr 18, 2018 08:34AM IsoRay (ISR) Preliminary Q3 Revenue of $1.57 Million
Apr 18, 2018 08:30AM IsoRay Announces Preliminary Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Year-over-Year Increase
Feb 8, 2018 04:05PM IsoRay Announces Second Quarter Fiscal 2018 Revenue of $1.54 Million, 50% Second Quarter-Over-Second Quarter Increase
Feb 8, 2018 08:00AM IsoRay Announces Study Published in Cureus entitled, “Resection Cavity Contraction Effects in the Use of Radioactive Sources (1-25 versus Cs‑131) for Intra-Operative Brain Implants”
Jan 31, 2018 08:00AM IsoRay Announces Second Quarter Fiscal 2018 Earnings Conference Call
Jan 24, 2018 08:10AM IsoRay (ISR) Reports Prelim. Q2 Revenue of $1.54M
View More Recent Stories View Older Stories